In the linear regression model, all clinical and molecular parameters (Bcl-2, P-gp, MRP1/ABCC1, BRCP/ABCG2, and survivin) were analyzed to determine the independent predictive factors for the DLBCL treatment resistance to the first-line treatment. This evidence concerns the gene PGP and diffuse large B-cell lymphoma.